BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25499288)

  • 1. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
    Rahman A
    Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
    [No Abstract]   [Full Text] [Related]  

  • 2. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani F; Cunningham D
    Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
    [No Abstract]   [Full Text] [Related]  

  • 5. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 6. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 7. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance treatment in metastatic colorectal cancer.
    Chibaudel B; Bonnetain F; Tournigand C; de Gramont A
    Lancet Oncol; 2015 Dec; 16(16):e583-4. PubMed ID: 26678202
    [No Abstract]   [Full Text] [Related]  

  • 9. Maintenance treatment in metastatic colorectal cancer.
    Simkens LH; van Tinteren H; Punt CJ; Koopman M
    Lancet Oncol; 2015 Dec; 16(16):e582-3. PubMed ID: 26678201
    [No Abstract]   [Full Text] [Related]  

  • 10. Maintenance therapy for metastatic colorectal cancer.
    Giampieri R; Cascinu S
    Lancet Oncol; 2015 Oct; 16(13):1281-2. PubMed ID: 26361970
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy for metastatic colorectal cancer.
    Rosales J; Leong LA
    J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
    Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
    Zhu LM; Zhao YZ; Ju HX; Liu LY; Chen L; Liu BX; Xu Q; Luo C; Ying JE; Yang YS; Zhong HJ
    Asian Pac J Cancer Prev; 2014; 15(16):6559-64. PubMed ID: 25169487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
    Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
    Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance treatment in metastatic colorectal cancer - Authors' reply.
    Hegewisch-Becker S; Graeven U; Arnold D
    Lancet Oncol; 2015 Dec; 16(16):e584-5. PubMed ID: 26678203
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
    Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
    Park LC; Lee HS; Shin SH; Park SJ; Park MI; Oh SY; Kwon HC; Baek JH; Choi YJ; Kang MJ; Kim YS
    World J Gastroenterol; 2012 Mar; 18(10):1104-9. PubMed ID: 22416186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Afonso S; Viani G; Afonso V; Stefano E; Afonso S
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.